Gaush Meditech (FRA:F7Y) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F7Y Gaush Meditech Ltd FRA:F7Y
60 GF Score
Price €0.49
GF Value €1.44
! 3 Warning Signs
View Full Analysis

What is Gaush Meditech 3-Month Share Buyback Ratio?

Gaush Meditech FRA:F7Y -2.80% 60 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates FRA:F7Y with a GF Score™ of 60/100 and a GF Value™ of €1.44. The stock has 3 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

FRA:F7Y
60GF Score
Gaush Meditech Ltd FRA:F7Y
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Gaush Meditech (FRA:F7Y) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Gaush Meditech and its competitors.
Is Gaush Meditech's 3-Month Share Buyback Ratio too high?
Gaush Meditech's current 3-Month Share Buyback Ratio is 0.00. Overall, Gaush Meditech has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's 3-Month Share Buyback Ratio compare to ABT and SYK?
Gaush Meditech's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Gaush Meditech and its competitors. Gaush Meditech's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Gaush Meditech (FRA:F7Y) has a current 3-Month Share Buyback Ratio of 0.00. The stock's GF Value™ is €1.44, compared to a current price of €0.49 — trading 66.3% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Gaush Meditech's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Gaush Meditech (FRA:F7Y), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gaush Meditech (FRA:F7Y) Overvalued in 2026?

Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued. The current stock price of €0.49 is trading 66.3% below its estimated GF Value™ of €1.44.

Key valuation signals for FRA:F7Y:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €1.44 vs. price of €0.49 (66.3% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the FRA:F7Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gaush Meditech Business Description

Other Exchanges 02407:Hong Kong
Address No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
60GF Score

Get the complete analysis for FRA:F7Y

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.49
Price
€1.44
GF Value